Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.49 |
| ▸ | FABP3 | P05413 | 6/20 | 0.54 |
| ▸ | FAAH | O00519 | 5/20 | 0.53 |
| ▸ | TERT | O14746 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28049027 | 1.00 | FABP3 (0.54) | FABP3FAAHTERTMAPTBLM | |
| SCHEMBL2905137 | 0.94 | FAAH (0.58) | FABP3FAAHTERTMAPTBLM | |
| Propane SCHEMBL741627 | 0.93 | FAAH (0.57) | FABP3FAAHTERTMAPTBLM | |
| Propane SCHEMBL28144123 | 0.93 | FAAH (0.57) | FABP3FAAHTERTMAPTBLM | |
| Propane SCHEMBL26102539 | 0.91 | FAAH (0.55) | FABP3FAAHTERTMAPTBLM | |
| SCHEMBL8432352 | 0.85 | FABP3 (0.70) | FABP3FAAHTERTMAPTBLM | |
| SCHEMBL16061965 | 0.84 | KMT2A (0.50) | FABP3MAPTHSD17B10FABP4PTPN1 | |
| SCHEMBL1720049 | 0.84 | KMT2A (0.50) | FABP3MAPTHSD17B10FABP4PTPN1 | |
| Phosphoric Acid SCHEMBL28049090 | 0.83 | FABP3 (0.62) | FABP3FAAHTERTMAPTBLM | |
| Propane SCHEMBL743689 | 0.83 | KMT2A (0.48) | FABP3MAPTHSD17B10FABP4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366507-A1 | Methods of Treating Neurologic Disorders | GEORGETOWN UNIVERSITY | 2024-11-07 | — | — | US | claimed |
| US-10668172-B2 | Treatment for exposure to nerve agent | GEORGETOWN UNIVERSITY (US) | 2020-06-02 | — | — | US | claimed |
| EP-2968598-B1 | TREATMENT FOR EXPOSURE TO NERVE AGENT | UNIV GEORGETOWN (US) | 2020-05-27 | — | — | EP | claimed |
| US-20180126004-A1 | TREATMENT FOR EXPOSURE TO NERVE AGENT | GEORGETOWN UNIVERSITY | 2018-05-10 | — | — | US | claimed |
| US-9878055-B2 | Treatment for exposure to nerve agent | GEORGETOWN UNIVERSITY (US) | 2018-01-30 | — | — | US | claimed |
| US-9480750-B2 | Preparation of antibody or an antibody fragment targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | GEORGETOWN UNIVERSITY (US) | 2016-11-01 | — | — | US | claimed |
| EP-2175835-B1 | METHODS FOR GENERATING IMMUNE RESPONSE USING CATIONIC-LIPOSOME-MEDIATED NUCLEIC ACID DELIVERY | UNIV GEORGETOWN (US) | 2016-04-20 | — | — | EP | claimed |
| US-20150252372-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2015-09-10 | — | — | US | claimed |
| US-20150224201-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2015-08-13 | — | — | US | claimed |
| US-9034330-B2 | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | GEORGETOWN UNIVERSITY (US) | 2015-05-19 | — | — | US | claimed |
| US-20070134154-A1 | Tumor-Targeted nanodelivery systems to improve early MRI detection of cancer | GEORGETOWN UNVERSITY (US) | 2007-06-14 | — | — | US | claimed |
| WO-2007047981-A2 | TUMOR-TARGETED NANODELIVERY SYSTEMS TO IMPROVE EARLY MRI DETECTION OF CANCER | GEORGETOWN UNIVERSITY (US) | 2007-04-26 | — | — | WO | claimed |
| US-20070065499-A1 | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | GEORGETOWN UNIVERSITY (US) | 2007-03-22 | — | — | US | claimed |
| EP-1595142-A4 | METHOD FOR EVALUATING THE EFFICACY OF CERTAIN CANCER TREATMENTS | UNIV GEORGETOWN (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1633327-A1 | METHOD FOR IMPROVING STABILITY AND SHELF-LIFE OF LIPOSOME COMPLEXES | GEORGETOWN UNIVERSITY (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1595142-A2 | METHOD FOR EVALUATING THE EFFICACY OF CERTAIN CANCER TREATMENTS | GEORGETOWN UNIVERSITY (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050002998-A1 | Method for improving stability and shelf-life of liposome complexes | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | US | claimed |
| WO-2005000271-A1 | METHOD FOR IMPROVING STABILITY AND SHELF-LIFE OF LIPOSOME COMPLEXES | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040241088-A1 | Method for evaluating the efficacy of certain cancer treatments | GEORGETOWN UNIVERSITY | 2004-12-02 | — | — | US | claimed |
| WO-2004066946-A2 | METHOD FOR EVALUATING THE EFFICACY OF CERTAIN CANCER TREATMENTS | GEORGETOWN UNIVERSITY (US) | 2004-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224201-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | CHMP4B, PLTP, FCGRT | KCNH2 2946/4885FABP3 1875/4885FAAH 1658/4885 |
| US-20070065499-A1 | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | CHMP4B, FCGRT, EXOSC5 | KCNH2 2689/4885FABP3 2159/4885FAAH 2406/4885 |
| US-20150252372-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | CHMP4B, FCGRT, EXOSC5 | KCNH2 2750/4885FABP3 2087/4885FAAH 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.